世界のバイオシミラー（Biosimilars）市場展望2018...市場調査レポートについてご紹介

1. Analyst View
2. Research Methodology
3. Biologics Market Outlook to 2018
3.1 Market Size
3.2 Market Segmentation
4. Market Trends & Drivers
4.1 Emerging Markets to Play a Pivotal Role in the Growth of Biosimilars
4.2 Rising Business Alliances Aiding in Biosimilar Development
4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
5. Biosimilars Market Outlook to 2018
5.1 Market Size
5.2 Market Segmentation
5.2.1 Erythropoietin
5.2.1.1 Scientific Insight
5.2.1.2 Market Analysis
5.2.1.3 Recent Activities
5.2.2 Human Growth Hormone
5.2.2.1 Scientific Insight
5.2.2.2 Market Analysis
5.2.2.3 Recent Activities
5.2.3 G-CSF
5.2.3.1 Scientific Insight
5.2.3.2 Market Analysis
5.2.3.3 Recent Activities
5.2.4 Monoclonal Antibody
5.2.4.1 Scientific Insight
5.2.4.2 Market Analysis
5.2.4.3 Recent Activities
5.2.5 Human Insulin
5.2.5.1 Scientific Insight
5.2.5.2 Market Analysis
5.2.5.3 Recent Activities
5.2.6 Interferons
5.2.6.1 Scientific Insight
5.2.6.2 Market Analysis
6. Major Geographical Market
6.1 US
6.1.1 Market Analysis
6.1.2 Regulatory Analysis
6.1.3 Recent Activities
6.2 Europe
6.2.1 Market Analysis
6.2.2 Regulatory Analysis
6.2.3 Recent Activities
6.3 India
6.3.1 Market Analysis
6.3.2 Regulatory Analysis
6.3.3 Recent Activities
6.4 China
6.4.1 Market Analysis
6.4.2 Regulatory Analysis
6.4.3 Recent Activities
6.5 Korea
6.5.1 Market Analysis
6.5.2 Regulatory Analysis
6.5.3 Recent Activities
7. Competitive Landscape (Key Products & Recent Activities)
7.1 US
7.1.1 Hospira
7.2 Europe
7.2.1 Stada Arzneimittel
7.2.2 Hexal AG
7.2.3 Ratiopharm GmbH
7.2.4 Sandoz GmbH
7.2.5 Bioton
7.3 India
7.3.1 Dr.Reddy’s Labs (DRL)
7.3.2 Intas Pharmaceuticals Ltd.
7.3.3 Biocon Limited
7.3.4 Wockhardt Limited
7.3.5 Shantha Biotechnics Limited
7.3.6 Reliance Life Sciences
7.4 China
7.4.1 3 SBio Inc.
7.5 Korea
7.5.1 LG Life Sciences
7.5.2 Celltrion Pharm Inc.
7.5.3 Dong-A Pharmaceutical Co., Ltd
7.6 Others
7.6.1 Teva

List of Figures:

Figure 3-1: Global – Biologics Market (Billion US$), 2013-2018
Figure 3-2: Global – Biologics Market by Segment (%), 2013
Figure 5-1: Global – Biosimilars Market (Million US$), 2013 & 2018
Figure 5-2: Global – Biosimilars Market by Key Segment (%), 2013
Figure 5-3: Global – Biosimilars Market by Key Segment (%), 2018
Figure 5-4: Global – Erythropoietin Biosimilars Market (Million US$), 2013 & 2018
Figure 5-5: Global – HGH Biosimilars Market (Million US$), 2013 & 2018
Figure 5-6: Global – G-CSF Biosimilars Market (Million US$), 2013 & 2018
Figure 5-7: Global – mAb Biosimilars Market (Million US$), 2013 & 2018
Figure 5-8: Global – Insulin Biosimilars Market (Million US$), 2013 & 2018
Figure 5-9: Global – Interferon Biosimilars Market (Million US$), 2013 & 2018

List of Tables:

Table 5-1: Global Biosimilar Market – Key Players by Rank
Table 5-2: Global – Biosimilar EPOs Approved for Marketing
Table 5-3: Global Biosimilar EPO Market – Key Players by Rank
Table 5-4: Global – Biosimilar EPOs in Pipeline
Table 5-5: Global – Patent Expiry Status of EPOs
Table 5-6: Global – Biosimilar HGH Approved for Marketing
Table 5-7: Global Biosimilar HGH Market – Key Players by Rank
Table 5-8: Global – Biosimilar HGH in Pipeline
Table 5-9: Global – Biosimilar G-CSF Approved for Marketing
Table 5-10: Global Biosimilar G-CSF Market – Key Players by Rank
Table 5-11: Global – Biosimilar G-CSF in Pipeline
Table 5-12: Global – Patent Expiry Status of G-CSF
Table 5-13: Global – Biosimilar mAbs Approved for Marketing
Table 5-14: Global Biosimilar mAb Market – Key Players by Rank
Table 5-15: Global – Biosimilar mAbs in Pipeline
Table 5-16: Global – Patent Expiry Status of mAbs
Table 5-17: Global – Biosimilar Insulin Approved for Marketing
Table 5-18: Global Biosimilar Insulin Market – Key Players by Rank
Table 5-19: Global – Biosimilar Insulin in Pipeline
Table 5-20: Global – Patent Expiry Status of Insulin
Table 5-21: Global – Biosimilar Interferons Approved for Marketing
Table 5-22: Global – Biosimilar Interferons in Pipeline
Table 5-23: Global – Patent Expiry Status of Interferons
Table 6-1: Biosimilars of US-based Companies Approved for Marketing
Table 6-2: Biosimilars of US-based Companies in Pipeline
Table 6-3: US – Patent Expiry Status of Biologics
Table 6-4: Biosimilars of European Companies Approved for Marketing
Table 6-5: Biosimilars of European Companies in Pipeline
Table 6-6: Europe – Patent Expiry Status of Biologics
Table 6-7: Biosimilars of Indian Companies Approved for Marketing
Table 6-8: Biosimilars of Indian Companies in Pipeline
Table 6-9: Biosimilars of Chinese Companies Approved for Marketing
Table 6-10: Biosimilars of Chinese Companies in Pipeline
Table 6-11: Biosimilars of Korean Companies Approved for Marketing
Table 6-12: Biosimilars of Korean Companies in Pipeline
Table 6-13: Korea – Patent Expiry Status of Biologics